Formulation-Development and In-Vitro-In Vivo Evaluation of Gastroretentive Floating Tablet Incorporating Clarithromycin by Mehetre, Gautam D. & Dubey, A
Mehetre et al                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(5):67-81 
ISSN: 2250-1177                                                                                [67]                                                                             CODEN (USA): JDDTAO 
Available online on 15.09.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits 
unrestricted non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                Research Article  
Formulation-Development and In-Vitro-In Vivo Evaluation of 
Gastroretentive Floating Tablet Incorporating Clarithromycin 
Gautam D. Mehetre*1, Dubey A2 
1 Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India 
2 Department of Pharmaceutical Science, Chatrapati Shahu Ji Maharaj University, Kanpur, India 
 
ABSTRACT  
The objective of the work is to summarize the applicability, manufacturing possibilities, excipients and the types of floatin g drug delivery 
systems and to optimize a floating, mucoadhesive system using Clarithromycin as the drug aiming at the eradication of Helicobacter 
pylori having desired floating and drug release properties based on preliminary excipient examination. Direct compressed (DC)  tablet 
was chosen as dosage form being a cost-effective technology for pharmaceutical industry requiring fewer procedures. Before the 
implementation of the pharmaceutical technological aims, analysis of critical factors influencing the manufacture was carried out. 
Reproducible manufacturing processes are required to achieve suitability and tablets uniformity to achieve the uniform properties of 
tablets, which could influence experimental parameters. Ishikawa diagram evaluation was created, which is a commonly used graphical 
method to identify factors resulting in an overall effect on product design and quality imperfection. The aim was to reveal affecting 
factors on uniformity of DC tablets in order to standardize all possible conditions and adjustments. Critical factors are indicated 
separately in particular method sections. 
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1. INTRODUCTION: 
The most frequent application of medicines is the peroral 
way of administration, which provides easy to take 
option, relatively low therapeutic cost, various 
formulations and applicable technologies 1. Its spread is 
shown by the fact that more than 50% of commercially 
available medicines are orally applied preparations 2. 
Higher patient compliance may be experienced due to 
their easy application. Although among the per os 
administered preparations, few are designed with 
biopharmaceutical aspect meeting with the physiological 
environment of the dosage forms. While until the 90’s 
not much, however nowadays more frequently modified 
drug delivery systems are designed containing special 
excipients and/or manufactured with special 
technological methods1. With novel preparations having 
controlled release, patient compliance can be increased 
more, namely multiple daily administrations can be 
reduced to once a day administration. Another advantage 
can be a local drug delivery, with which not only the 
administration of the medicine can be improved, but also 
the site-specific efficiency of a particular applied active 
pharmaceutical ingredient (API) may be optimized. 
Based on the Dévay’s proposal biopharmaceutical 
classification system of pharmaceutical preparations, the 
following classes of drug delivery systems can be 
distinguished 1: 
1.1 Time controlled systems based on the effect of time 
after their administration and the time interval of 
effect can be the following: 
1.1.1 Rapid (e.g. solutions, effervescent preparations, fast 
dissolving or disintegrating tablets), 
1.1.2 Sustained (e.g. extended tablets or tablet implants), 
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1.1.3 Delayed (e.g. enteric coated tablets) and, 
1.1.4 Pulsatile drug delivery (e.g. repeated bursts of API 
dissolution) preparations. 
1.2  Site-controlled systems, which can be: 
1.2.1 Approaches with direct administration of medicine 
(e.g. directly into muscle or joint) to the target 
organ or, 
1.2.2 Passive and active targeted drug delivery systems: 
1.2.3 Passive targeting: nanotechnological drug delivery 
systems, which are based on accumulation of the 
drug in the areas around the tumor due to EPR 
(enhanced  permeability and retention) effect3, 
1.2.4 Active targeting: nanotechnological drug delivery 
systems, which are able to identify target cells (e.g. 
tumor cells) and to bound and penetrate into them 
in  order to achieve specific effect3, 
1.3    New types of preparations, i.e. site- and time-
controlled systems, the purpose of Combination of 
the preiviously listed two main classes. 
The modification of drug release is always performed to 
achieve a particular therapeutic aim, with which 
optimized bioavailability of API(s) can be reached by 
taking the physiological environment into consideration. 
In the cases of APIs with short elimination half-life, long 
acting preparations can be designed with the 
prolongation of API release and absorption. On the other 
hand, some acute or emergency cases require the 
possibility of the most rapid effect of the API, which can 
be developed by the fast API release from preparations. 
Modified drug delivery systems (MDDSs) can be 
classified based on the time and location of drug release. 
With per os administered medicines, the location of drug 
release in the gastrointestinal tract (GIT) may be in: the 
mouth (e.g. orodisperse, sublingual, buccal DDSs), the 
stomach (e.g. floating, expandable DDSs), the small 
intestine and/or the colon (e.g. intestinosolvent, 
enterosolvent, colon targeted DDSs). Thus the location of 
drug release can be controlled with an appropriate 
modification of the preparation, with which site-
controlled systems can be achieved. During drug release 
in the oral cavity or in the stomach, not only systemic but 
also local effects may be taken into consideration, while 
drug release in the small intestine may be expected to be 
predominantly systemic. In colon-specific therapy, 
mostly local effects may develop, since absorption is 
limited/ minimal. Those modified drug delivery systems, 
in which the modification is aimed at prolonging the 
residence time (GRT), are termed gastroretentive drug 
delivery systems (GRDDS). Via the modification of the 
time spent in stomach, site- and time-controlled systems 
may be achieved. Based on the applied technology, 
gastroretentive systems can be classified into four 
separate groups explained as under: 
1.4 Expandable drug delivery systems hinder their 
transfer through the pylorus with their expansion, 
swelling via their size without causing gastric 
obstruction 4, 5. 
1.5 High density drug delivery systems involve 
formulations of dosage forms having higher average 
density, than physiological stomach content. Application 
of high density ingredients are required to use such as 
barium sulfate (4.50 g/cm³), zinc oxide (5.61 g/cm³), 
titanium dioxide (4.23 g/cm³). For significant 
prolongation of GRT, 2.5 g/cm³ average density is 
necessary 6. 
1.6 Floating drug delivery systems (FDDS) are those 
preparations, which are capable for buoyancy on the 
surface of gastric medium after a particular time. The 
mechanism of flotation depends on the applied 
technology. During flotation, preparations have bulk 
density lower than the gastric fluid (ρ<1.00 g/cm3) and 
can remain buoyant without influencing gastric 
emptying rate. This results in the prolongation of gastric 
residence time and better control on drug release. 
1.7 Mucoadhesive drug delivery systems are capable for 
bioadhesion onto gastric mucosa resulting in sustaining 
of GRT, which may cause enhancement of drug 
absorption in a site-specific manner. Special polymers 
having mucoadhesive ability are indispensable to apply 
in these systems, which can adhere to the epithelial 
surface of the stomach 7. Mucoadhesion may be an 
approach, which can be combined with former 
mentioned technologies in order to achieve not only 
physically but also chemically resulted gastric retention. 
1.8 Rationale behind selection of Clarithromycin as 
suitable drug 
Clarithromycin is rapidly and well absorbed from the 
gastrointestinal tract – primarily in the jejunum – but 
undergoes extensive first-pass metabolism after oral 
administration. The absolute bioavailability of a 250-mg 
clarithromycin tablet is approximately 50%.  This spatial 
absorption window of clarithromycin makes it a suitable 
candidate to develop it as a floating drug delivery 
system. Clarithromycin is rapidly and extensively 
metabolized in the liver. It has elimination half life of 
about 2-4 hours, which adds to its suitability for 
development as gastroretentive floating drug delivery 
system. 
2. MATERIALS AND METHODS 
Paracetamol is used as API in preliminary studies, then 
followed by clarithromycin as the main drug; Hydroxy 
propyl cellulose grade B1 and 11, sodium alginate as 
gelling agent, sodium bicarbonate as gas generating 
agent, barium sulfate as X-Ray contrast material, 
Methanol for clarithromycin assay by high performance 
liquid chromatography (HPLC), potassium dihydrogen 
phosphate for clarithromycin assay by HPLC, Krebs-
Hensley buffer containing D-glucose, magnesium sulfate, 
potassium phosphate monobasic, potassium chloride and 
sodium chloride for ex vivo mucoadhesion studies. 
Preliminary – and optimization experiments have been 
carried out. Principal aim of the research work was the 
optimization of floating drug delivery system, but the 
preliminary project and its conclusions were needed to 
begin designing of optimization project. The Method 
section contains all method descriptions, which were 
used either during preliminary or optimization studies. 
2.1 Preformulation methods 
Particle size and shape parameter measurements were 
done with microscopic examination with the use of 160x 
and 640 x magnifications (Zeiss, Axio Imager A1 
Microscope, Germany) based on 50 largest separated 
particles. 
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Sphericity (Ψ) was calculated with the following formula:  
 
Sphericity of particles describes the form of region on 
the bases of their circularity. Numerical range is from 0 
to 1. The value of the sphericity for a perfect round shape 
particle is 1. Filled area (Af) is the region including any 
holes on it. Crofton perimeter (Pcr) determines circular 
region with correction optimized for circular objects. 
Zeiss Axio Vision Rel. 4.7 software (Carl Zeiss, Germany) 
was used for digital photo analysis. 
2.2 Flowability and density 
Flow properties of L-HPC 11 and B1 were examined to 
highlight further physical differences. Determination of 
angle of repose was performed according to 2.9.16. Test 
of Ph. Eur. Ed. 5.0. Measurements were carried out in 
triplicate. Angle of repose was calculated. Apparent 
density examination was carried out by a volumetric 
device (Erweka SVM 121, Germany) according to 2.9.15. 
Ph. Eur. 5.0. Bulk densities (ρbulk) were recorded after 
filling 100.0 g material into graduated cylinder; tapped 
densities (ρtapped) were recorded after 1250 taps. Using 
these measurements Carr’s indices (Ci) 9 was calculated. 
Hausner’s ratios (Hr) were also determined by using the 
ratios between tapped and bulk density of powders. 
2.3 Wettability 
Force tensiometer (KSV, Sigma 701) was applied to 
measure water uptake of the L-HPC types. Glass sample 
holder vessel was used with 1.15 mm width and with 
1.00 mm diameter glass filter at the bottom holding 50.0 
mg of samples. The materials were immersed into 
distilled water and 0.1 M hydrochloric acid for 60 
minutes respectively. Sampling was done in every 5 
seconds. Accuracy of force tensiometer instrument was 
0.01 mg. Wettability tests were performed in triplicate. 
2.4 Rheological behavior of sodium alginate 
Viscosity grade of sodium alginate was examined with 
the use of rotational viscometer (Anton PaarRheolab QC, 
Austria) with standard measuring system (CC27). 
Temperature dependence of viscosity and flow curves of 
1.0 % sodium alginate solution were also determined at 
20, 25, 30, 35, 37 ºC. Viscosity measurements were 
performed with 100 1/s constant shear rate. Rheological 
(flow curve) behavior studies were carried out with 
linear increase of shear rate from 10 to 500 1/s. Three 
parallel samples were examined. Flow behavior indices 
(z) of 1 % sodium alginate solutions at different 
temperature were also calculated based on the Ostwald-
de Waele power law model 10. 
2.5 Drug-excipients interaction studies 
Differential Thermal Analysis (DTA) 
Differential thermal analyzer (Shimadzu DTA-50, Japan) 
was applied for thermal analysis of Clarithromycin and 
Clarithromycin-excipient blends. Clarithromycin and 
excipients were analyzed separately as well as blends 
with drug-excipient ratios according to the optimized 
composition (MF_OPT). 10.0 mg of individual samples 
and blends were scanned in the temperature range of 25-
400 ºC under air atmosphere. Temperature rate was 5 
ºC/ min. Peak shifting and melting point were evaluated 
on thermo grams in order to detect interaction between 
Clarithromycin and excipients. Three parallel 
examinations were carried out. 
3. EXPERIMENTAL DESIGN, STATISTICAL 
ANALYSIS AND OPTIMIZATION 
Several statistical approaches of experimental design 
originate from the work of R. A. Fischer. In the early 20th 
century, he showed how important it is to appropriately 
consider the design and the execution of experiments 
before they are actually performed to prevent frequently 
encountered problems. 
Design of experiments (DOE) belongs to the field of 
applied statistics, which deals with planning, analyzing 
and interpreting controlled studies. Afterwards the data 
have been gained from experiments they are objectively 
evaluated in order to understand the mathematical 
relation between factors (independent variables) and 
responses (dependent variables). With the application of 
DOE, fewer experiments are enough to explore their 
correlation. 
The experimental design contains its settings, sequence 
and is created with the choice of layout type before 
beginning the studies. Choice of used layout depends on 
the experimental aim(s). One of the most important aim 
of DOE is the optimization and assessment of the 
influence of factors on responses. After objective 
evaluation of result data, optimization criteria have to be 
determined based on the desirable responses. 
In this work, Design Expert 7.0.0 software was used in 
order to create the experimental design and response 
surface plots. Data obtained from the floating tablet 
properties were analyzed with this software, too. 
Polynomial models were generated for all responses 
including linear, quadratic as well as interaction terms. 
The best model was chosen based on the particular 
statistical parameters involving coefficient of variation 
(CV), regression coefficient (R2) and p-value. The 
following mathematical equation form was used to 
evaluate numerical effect of independent variables on 
responses: 
Where Y is the response variable, b0 is the intercept, bi is 
the estimated coefficient of factors. X1, X2 and X3 are the 
main effects representing how responses change, when 
an individual factor changes. Interaction term (X1X2) 
shows the effect of simultaneous change of factors on 
responses. Xi2 is the quadratic effect for evaluation of 
non-linear correlations. 
In this work, two experimental designs were applied. 
3.1 The preliminary study focused on the influence of L-
HPC 11, B1 and their 1:1 mixture on certain properties of 
sodium alginate based floating drug delivery systems. In 
this project, face centered central composite design 
(α=1) was applied with two numerical factors (X1, X2) 
and with three-levels (+1, 0, -1). One categorical factor 
was used involving the types of two L-HPCs and 1:1 
mixture of L-HPCs. The two numerical independent 
variables were the sodium alginate (X1) and particular L-
HPC type (X2). 
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Factors mean the concentrations (%) of the materials in 
the floating tablets. All tablets contained 150 mg 
paracetamol and fixed amount of excipients contributing 
effervescent effect and tablet compressibility. 
Experimental layout is shown in (Table 1). Dependent 
variables were the following: floating time, floating lag 
time, floating force, swelling capability and drug 
dissolution.
 
Table 1 Experimental layout of preliminary project 
Exp. 
No. 
Sodium 
alginate, 
X1 (%) 
L-HPC 
11, X2 
(%) 
Exp. 
No. 
Sodium 
alginate, 
X1 (%) 
L-HPC 
B1, X2 
(%) 
Exp. 
No. 
Sodium 
alginate, 
X1 (%) 
L-HPC 
11:B1, X2 
(%) 
PFS01 0.50 0.50 PFS10 0.50 0.50 PFS19 0.50 0.50 
PFS02 35.15 0.50 PFS11 35.15 0.50 PFS20 35.15 0.50 
PFS03 0.50 25.00 PFS12 0.50 25.00 PFS21 0.50 25.00 
PFS04 35.15 25.00 PFS13 35.15 25.00 PFS22 35.15 25.00 
PFS05 0.50 12.75 PFS14 0.50 12.75 PFS23 0.50 12.75 
PFS06 35.15 12.75 PFS15 35.15 12.75 PFS24 35.15 12.75 
PFS07 17.82 0.50 PFS16 17.82 0.50 PFS25 17.82 0.50 
PFS08 17.82 25.00 PFS17 17.82 25.00 PFS26 17.82 25.00 
PFS09 17.82 12.75 PFS18 17.82 12.75 PFS27 17.82 12.75 
 
3.2 For optimization of sodium alginate based floating 
tablets, face-centered central composite design (α=1) 
was used with three factors: sodium alginate (X1), L-HPC 
B1 (X2) and sodium bicarbonate (X3). Each factor was 
examined in three levels (+1, 0, -1). Each tablets 
contained 250 mg Clarithromycin and constant 
quantities of excipients contributing effervescent effect 
and tablet compressibility. Factors mean the 
concentrations of the materials in the floating tablets. 
Experimental layout is shown in (Table 2). Dependent 
variables were the following: floating lag time, maximal 
floating force, maximal floating force calculated to 100 
mg tablet mass, time needed for maximal floating force 
and drug dissolution. 
 
Table 2 Experimental layout of optimization project 
Exp. No. 
Sodium alginate, 
X1 (%) 
L-HPC B1, 
X2 (%) 
NaHCO3, 
X3 (%) 
Total tablet weight 
(mg) 
MF01 5.00 30.00 8.00 463.82 
MF02 15.00 30.00 8.00 569.48 
MF03 5.00 45.00 8.00 642.67 
MF04 15.00 45.00 8.00 865.05 
MF05 5.00 30.00 13.00 511.25 
MF06 15.00 30.00 13.00 642.67 
MF07 5.00 45.00 13.00 737.46 
MF08 15.00 45.00 13.00 1046.03 
MF09 5.00 37.50 10.50 569.48 
MF10 15.00 37.50 10.50 737.46 
MF11 10.00 30.00 10.50 538.79 
MF12 10.00 45.00 10.50 796.18 
MF13 10.00 37.50 8.00 603.86 
MF14 10.00 37.50 13.00 686.81 
MF15 10.00 37.50 10.50 642.67 
 
3.3 Formulation studies 
3.3.1 Preparation of effervescent floating tablets 
Ingredients of tablets were accurately measured with 
analytical balance (Kern, ABJ 220-4M, Germany). Powder 
blends were mixed every time after adding next 
substance for 3 minutes with the use of mortar and 
pestle, and finally all the blends were mixed for 10 
minutes. The flow properties of blends were qualified to 
be suitable for direct compression. Eccentric single-
punch tablet press was used using 8, 10, 12 mm round 
concave punches. Compression forces at all batches were 
adjusted to achieve 50±5 N tablet hardness. Tableting 
was performed and stored at 50±10% relative humidity 
(RH), at 25±5 °C. 
3.3.2 Studies of floating behavior 
Floating lag time (tlag) is the period from the immersion 
of the tablet until its buoyancy. Experiments were 
carried out in 450 ml 0.1 M hydrochloric acid at 37±0.5 
°C. Durations of floating lag time were visually recorded 
by camcorder (DCR-SX85E, Sony, Japan). Each test was 
carried out for 4 hours in triplicate. The process of 
floating lag time measurements is shown in below figure.
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Fig. 1 The processes of floating lag time measurements 
3.3.3 Floating force study 
Floating force measurements were carried out based on 
the theoretical base described by Timmermans and 
Moes. 11, 12 KSV Sigma force tensiometer (KSV 
Instruments Ltd, Helsinki, Finland) was used with 0.1 mg 
accuracy. Tablets tested in a standard vessel containing 
450 ml 0.1 M HCl, in which a special filtering plate with 2 
mm aperture size was applied. Majority of developing 
carbon dioxide bubbles passed through the filter plate 
resulting less noise. Media were exposed with 
ultrasound to avoid gas formation on filtering plate. 
During the test, the weight of the filtering plate was 
continuously measured. Floating tablets pushed the 
filtering plate vertically upward; hence change of the 
weight could be registered as a function of time. 
Evaluated parameters were the following: 
 Maximal floating force (Fmax), 
 Time (tFmax) needed for maximal floating force, 
 Time (tF1/2) required for 50 % of maximal floating 
force, 
 Maximal floating force calculated for 100 mg tablet 
mass (Fmax/100mg). 
Floating forces were calculated based on the formula 
described by Cromer 13: 
 
In the equation, Ffloat is the floating force expressed 
vertically upward by a floating tablet. F0 equals with the 
multiplication of filtering plate mass in medium with 
gravitational acceleration (g), which was constantly 
39.84 mN. mt is the weight measured by the devices, 
when a tablet pushed the plate upward. mt is the 
negative weight gradient caused by the tablet directly, 
which was calculated by subtraction of mt from m0. In 
absolute value, mt is the weight expressed by the 
buoyancy of floating tablets. All experiments were 
performed in triplicate. 
3.3.4 Determination of swelling capability 
Swelling capacities of floating tablets were measured 
based on the method described by Dorozyn ski et al. 14. 
Tablets were weighed (W1), then immersed into glass 
beaker filled with 200 ml of 0.1 M hydrochloric acid at 
37±0.5 °C. At time 30, 60, 120, 180 and 240 minutes, 
tablets were removed from the beaker. After wiping the 
excess liquid from surface, tablets were reweighed (W2). 
Swelling index (Si) was calculated. 
3.3.5 Drug release studies 
In vitro dissolution studies of all floating tablets were 
performed according to Ph. Eur. 2.9.3 dissolution test 
with paddle apparatus. Stirring speed was 50 RPM 
(Erweka DT-700, Germany), the medium was 900 ml 0.1 
M HCl tempered to 37± 0.5 °C. Dissolution tests for 
preliminary project were done for 4 hours, for 
optimization project were performed for 6 hours. During 
the studies, 2.5 ml samples were taken at 10, 15, 20, 30, 
45, 60, 90, 120, 180, 240, 300 and 360 minutes. Each 
sample was filtered through PTFE membrane. All 
measurements were done in triplicate. 
Active substance contents of samples were determined 
with spectrophotometric method (Jasco V-670, Japan) at 
their absorption maximum (paracetamol, λpmax=243 
nm; Clarithromycin, λmmax=277 nm). Linear calibration 
curve was previously created; all samples were 
measured within this concentration interval. 
In optimization project, dissolution studies of two 
commercially available Clarithromycin tablets (Klion® 
250 mg and, Supplin® 250 mg) were also performed for 
comparison with optimized floating tablets. 
3.3.6 Kinetics of drug release 
Model dependent evaluations of dissolutions were 
carried out with four mathematical models. Zero order -, 
first order -, Higuchi - and Weibull kinetic models were 
used to describe the drug release from floating tablets 15. 
Fundamentals of first order kinetics were first described 
by Noyes-Whitney equation which was later modified 
several times by Brunner et al. 16, then Hixson and 
Crowell. The model can be applied in dosage forms such 
as porous matrices containing water-soluble drugs 17. 
The first model Higuchi’s kinetics for planar 
homogeneous matrix system was used accordingly 18. 
Weibull’s model is a commonly used model, which fits 
various kinds of dissolution profiles 19. During evaluation 
linear transformation was carried out on each 
dissolution profile and the equation of the fitted linear 
line was determined according to the following formula: 
 
Where Qt is the drug dissolved in time t, s is the slope of 
the line, ndiss is y-intercept. 
3.3.7 Ex vivo mucoadhesion studies 
Two most frequently performed mucoadhesion studies 
were done: the detachment force and rheological 
mucoadhesion measurements. The former was 
performed with rat gastric mucosa, the latter one with 
extracted rat gastric mucus. 
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Wistar rats (250-350 g) were bred in a temperature-
controlled room having a 12 h light/dark cycle, provided 
with standard rodent chow and water ad libitum. For 
harvesting the gastric mucosa, rats were deeply 
anaesthetized with sodium thiopental (100 mg/kg I.P.) 
and killed by cervical dislocation and exsanguinations. 
The abdomen was opened; the stomach was excised and 
cut open along the lesser curvature. Stomachs were 
stored in Krebs-Henseleit solution until their further use. 
Gastric content was gently emptied and the mucosa was 
rinsed with 0.1 M HCl solution containing 0.9 % sodium 
chloride (NaCl). 
3.3.8 Detachment force studies 
Detachment force studies were carried out according to 
the modified surface tensiometer method 21-24. Inner 
surface of stomach mucosa was outspread on 10 % agar-
agar gel immobilized with pins. Tablets were fixed with 
ethyl 2-cyanoacrylate on the bottom of a special 
specimen hanged on a tensiometer arm (KSV 
Instruments Ltd, Finland). Before measurements, 
mucosae were wetted with 20.0 µl 0.1 M HCl containing 
0.9 % NaCl in order to achieve better mucoadhesive 
performance. Tablets were left on mucosae surface for 3 
minutes. 
Maximal detachment forces were recorded and 
calculated in mN with the following equation: 
Where Fdetach is the detachment force, Ftotal is the 
measured total weight and Ftablet is the weight of tablet. 
Structure of measuring method is depicted in (Fig.2). 
Samples were tested in triplicate. 
 
Fig. 2. Structure of tablet detachment force testing 
apparatus 
3.3.9 Rheological mucoadhesion studies 
Rheological ex vivo mucoadhesion measurements were 
carried out based on literature 25,26. Gastric mucus was 
carefully removed under operating microscope, after 
which it was put into 0.1 M HCl containing 0.9 % NaCl. 
Dispersion with high speed homogenizer (Ultra-Turrax® 
T 25, IKA®, Germany) with 9500 RPM for 2 minutes was 
performed to achieve homogeneous sample. The mucus 
then was centrifuged with 5500 RPM for 1 hour. Pellets 
were dialyzed with Membra-Cel® dialysis tubing (Serva 
MWCO 3500, Germany) on 4 ˚C for 24 hours. Mucus was 
again centrifuged (Labogene 1524, Denmark) with 
15000 RPM for 1 hour. Pellets were stored at -15 ˚C until 
further use 27,28. 
3 % mucus solution and optimized formulation 
equilibrated to 3 % L-HPC and sodium alginate were 
dispersed separately in 20 ml 0.1 M HCl. Then mixture of 
3 % mucus and MF_OPT equilibrated to 3 % L-HPC and 
sodium alginate were also prepared. 
Flow curves of samples were examined in a rotational 
viscometer (Anton PaarRheolab QC, Austria) at 37 °C. 
Data were recorded in a 0-25 s-1 shear rate interval. 
Increase of viscosity due to mucoadhesion (ηm) was 
calculated with the following formula:                                                
 
Where, ηtotal is the viscosity of mucus/tablet mixture, 
ηtabl equilibrated to 3 % L-HPC and sodium alginate and 
ηmucus solution. All experiments were performed in 
triplicate. 
3.3.10 In vivo X-ray CT evaluation of floating tablets 
in rat 
Clarithromycin optimized tablets (optimization project) 
were studied in Wistar rats (n=5). For visualization and 
detection floating tablets, barium sulfate (BaSO4) X-ray 
contrast material was used. 10 % of the optimized blend 
was replaced with BaSO4. The homogenized blend was 
pressed with 3 mm round concave punches by eccentric 
single-punch tablet press.  
Before the experiment, rats were kept at room 
temperature in 12 hour light and dark cycle. The animals 
were not fasted, food and water were supplied ad 
libitum. Imaging was performed at the following 
sampling  times:  5 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h and 48 
h. Image at 48 hours after administration was examined 
that floating tablets did not caused gastrointestinal 
obstruction. 
Reconstructed, reoriented and co-registered images 
were further analyzed by dedicated image analysis 
software products by placing appropriate volume of 
interests (VOI) on the tablets. Linear attenuation data 
were reconstructed into Hounsfield units (HU). Then a 
second, more detailed, lookup table (LUT) (indicated 
with different colors) was used by image processing to 
visualize spectacularly the differences of attenuation 
values of voxels ordered to the tablets VOIs 29. 
4. RESULTS AND DISCUSSION 
4.1 Preformulation methods 
4.1.1 Comparative physical examination of L-HPC 11 
and L-HPC B1 
The photo analysis of L-HPC particles showed 
differences in shape and in size. (Fig.3). L-HPC 11 had 
longitudinal shape, while L-HPC B1 formed similar to 
spheroidal particles. Their shapes were characterized 
numerically with sphericity index. Sphericity index in the 
case of L-HPC 11 was 0.19±0.08, while in the case of L-
HPC B1 was 0.48±0.18. The result showed that L-HPC B1 
is more similar to ideal spherical particles (Ψ=1.0) than 
L-HPC 11, but its shape is far from sphere shape.
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Fig. 3. Microscopic appearance of a) L-HPC 11 and b) L-HPC B1 particles 
 
Particle sizes of L-HPC 11 and B1 were also differed. 
From both materials, 50 particles were evaluated. In the 
case of L-HPC B1, average size was 44.01±10.59 µm 
compared to L-HPC 11 with 246.35±82.03 µm average 
size. 
Wettability of 50.0 mg pure L-HPCs were examined in 
order to reveal further difference between their 
physicochemical properties. All tests were performed in 
purified water and in 0.1 M hydrochloric acid for 1 hour, 
but the powders absorbed most of the fluid in the first 1 
minute. Their liquid uptake and Wettability rate as a 
function of time are shown in figure below.
 
 
Fig.4. Wettability and wettability rate of L-HPC 11 and B1 as a function of time. 
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Final wettability values of examined L-HPCs are shown in Table 3. The result showed that wettability of both materials 
was lower in 0.1 M HCl than in distilled water, however, the rate of fluid absorption was higher in 0.1 M HCl. L-HPC B1 
showed faster and more intense liquid absorption compared to L-HPC 11. 
Table 3. Total wettability of L-HPC 11 and L-HPC B1 after 1 hour 
Total wettability of 50 mg L-HPCs Distilled water (mg) 0.1 M HCl (mg) 
L-HPC 11 483.7±22.8 451.0±17.4 
L-HPC B1 522.7±36.6 480.0±39.6 
 
Both values (Carr’s index and Hausner’s ratio) characterizing powder flowability showed better flowability of L-HPC B1. 
The differences manifested also in tapped (ρt) and bulk (ρb) densities. 
Table 4. Flow characteristics and densities of L-HPC 11 and L-HPC B1 
Samples ρt(g/cm3) ρb(g/cm3) Carr’s index Hausner’s ratio Angle of repose(°) 
L-HPC 11 0.443±0.001 0.356±0.008 22.91±0.32 1.24±0.04 48.77±1.67 
L-HPC B1 0.591±0.003 0.496± 1.012 19.05±2.31 1.19±0.02 39.24±0.86 
 
Demonstrated data (Table 4) revealed that flowability 
values differed between L-HPC types, but the differences 
are not remarkable. The largest deviation was in the case 
of angle of repose, which can have significant influence 
during filling the blend into dies. 
4.1.2 Rheological behavior of sodium alginate 
At the preformulation stage of experiments, rheological 
properties of sodium alginate were determined. High 
viscosity grade sodium alginate was applied during 
formulation, which was characterized specifically. The 
result showed significant dependence of sodium alginate 
viscosities on temperature. Measured viscosities are 
presented by (Table 5). 
Flow curve measurements showed non-Newtonian, 
pseudoplastic behavior showing decrease in viscosity 
caused by increase of shear rate. Calculated flow 
behavior indices are shown in Table 5, which 
demonstrates that rheological behavior changes with 
temperature. Increasing z value results in less change in 
viscosities caused by increase of shear rate. 
Table 5. Temperature dependence of viscosity and flow 
behavior index of 1 % sodium   alginate solutions 
t (°C) η (mPas) Z 
20 214.73±7.73 -0,6943 
25 196.88±7.02 -0,7139 
30 175.65±7.82 -0,7352 
35 157.12±6.60 -0,7601 
37 151.63±6.42 -0,7604 
 
4.1.3 Drug-excipients interaction studies 
Result of the thermo analytical method showed a sharp 
endothermic peak of pure Clarithromycin at 159.9 °C, 
which was considered as the melting point. Based on the 
composition of MF_OPT, all the excipients were blended 
with pure Clarithromycin separately. The samples did 
not show significant alteration of Clarithromycin melting 
point, which is between 159 and 163 °C according to the 
literature30. DTA thermograms of samples are shown in 
Fig. 5. Consequently, results of this study could not 
indicate any API-excipient interactions. 
 
 
Fig. 5. DTA thermograms of Clarithromycin and Clarithromycin-excipient blends according to MF_OPT composition. 
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4.2 Formulation results 
4.2.1. Studies of floating behavior 
In the section of floating behavior examinations, floating 
lag time, total floating time and vertically expressed 
floating force studies were performed and evaluated. 
The best fitting model on floating lag time (tlag) data 
was the linear model (p<0.01) and sodium alginate was 
the only significant factor (p<0.01) in the examined 
concentration ranges. In the lower level (-1) of sodium 
alginate (0.5 %) short tlag values were observed, which 
was 25.77±6.53 s. Increasing amount of sodium alginate 
resulted in longer time to achieve buoyancy. At higher 
sodium alginate levels (0, +1), maximal tlag value was 
520.30±20.79 s which can be considered to be long time 
to float, but only 8 % of sodium bicarbonate accelerated 
the flotation. 
On the total floating time (tfloating) data, quadratic 
model could be fitted and both numerical factors and 
their interactions showed significance (p<0.0001). At 0 
and +1 levels (17.82, 35.05 %) sodium alginate caused 
more than 4 hour flotation, since in the cases of tablets 
having 0.5 % sodium alginate more rapid disintegration 
could be observed, at which disintegrant effect of L-HPCs 
could prevail. L-HPC 11 resulted in faster disintegration. 
Floating lag time and total floating time data are shown 
in Table 6. 
 
Table 6 Data of floating lag time and total floating time 
Exp. No. tlag (sec) Tfloating(min) Fmax(mN) tFmax(s) 
PFS01 6.44± 5.19 21.7 ± 4.6 2.295 415.1 
PFS02 343.00 ±28.99 240.0 ± 0.0 1.549 14395 
PFS03 0.00± 0.00 7.1 ± 0.5 2.037 30.4 
PFS04 507.16± 100.35 240.0 ± 0.0 3.884 14295 
PFS05 0.00± 0.00 3.9 ± 0.3 2.363 15.3 
PFS06 10.16± 75.77 240.0 ± 0.0 1.904 14396 
PFS07 109.20± 89.32 240.0 ± 0.0 1.626 930 
PFS08 16.69± 1.58 240.0 ± 0.0 2.557 14398 
PFS09 520.30± 20.79 240.0 ± 0.0 1.780 13715 
PFS10 16.02± 6.58 28.6 ± 1.1 1.375 379.2 
PFS11 356.55± 47.07 240.0 ± 0.0 2.859 14398 
PFS12 0.00± 0.00 15.5 ± 3.0 1.292 45.6 
PFS13 230.16± 11.87 240.0 ± 0.0 4.606 3004.8 
PFS14 0.00± 0.00 15.3 ± 1.9 1.199 141.7 
PFS15 507.67± 161.30 240.0 ± 0.0 2.164 14386 
PFS16 273.45± 156.64 240.0 ± 0.0 0.925 14399 
PFS17 180.00± 51.64 240.0 ± 0.0 2.677 14119 
PFS18 106.14± 24.18 240.0 ± 0.0 2.06 14389 
PFS19 25.77± 6.53 35.7 ± 3.1 1.412 475.3 
PFS20 238.16± 13.25 240.0 ± 0.0 1.324 5450.9 
PFS21 13.87± 3.25 17.2 ± 1.3 1.273 45.6 
PFS22 417.22± 18.12 240.0 ± 0.0 3.270 14386 
PFS23 8.10± 2.62 13.3 ± 0.3 1.172 65.8 
PFS24 330.33± 27.79 240.0 ± 0.0 2.315 14398 
PFS25 307.71 ±174.70 240.0 ± 0.0 1.194 14398 
PFS26 344.00± 29.70 240.0 ± 0.0 2.217 14313 
PFS27 184.00± 24.64 240.0 ± 0.0 1.899 14393 
 
The floating force measurements have been performed 
for 4 hours. Among samples two patterns could be 
observed the rapid disintegrating and exponentially 
increasing patterns. On maximal floating force values 
(Fmax) data, two-factor interaction model was fitted 
(p<0.0001).Both numerical factors (p<0.0001) and their 
interactions (p=0.0004) showed significance. Categorical 
factor had no significance. On tFmax data, quadratic 
model was used due to its significant fitting. Time values 
for achieving maximal floating forces were only 
influenced significantly by sodium alginate (p<0.0001). 
Response curve of tFlag values as a function of L-HPC 
11/B1 mixture, and sodium alginate is depicted by 
(Fig.6.).   
Fig. 6. The effect of L-HPC 11:B1 mixture and sodium 
alginate on maximal floating force development time 
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4.2.2 Determination of swelling capability 
Swelling capabilities of polymers have one of the most 
important influences on the behavior in aqueous 
medium of floating tablets, which are basically matrix 
tablets. In matrix tablets, during the swelling process, 
aqueous medium reaches deeper layers of tablets with 
time, which process is generally driven by diffusion. Drug 
release of tablets is also affected by swelling, since 
diffusion creases hydration layers in the tablets resulting 
in outward diffusion of API. Inside the tablets, relatively 
dry core with low water content is followed by more 
hydrated layers, which are surrounded by the surface 
layer in contact with the medium. The hydration layers 
of PFS04 floating tablet (L-HPC 11: 25.0 %, Sodium 
alginate: 35.15 %) can be identified at 4 hour depicted by 
Fig.7 below. 
 
Fig.7. Macroscopic view of PFS04 floating tablets (L-HPC 
11: 25.0 %, sodium alginate: 35.15 %) after 4 hours of 
hydration 
Values of Si indices show the water uptake of tablets, 
which additionally were standardized for tablet weights. 
On the swelling capability data, linear model could be 
fitted with high significance (p<0.01). At Si values after 
30 minutes and 1 hour, sodium alginate was the only 
significant factor (p<0.01), but at 2 hours L-HPC (X2) was 
also significant (p<0.05). The categorical factor was not 
significant. Maximal swelling index (Si=2.357±0.067) 
was observed at PFS22 (L-HPC 11/B1: 25.0 %, sodium 
alginate: 35.15 %), which is significantly higher, than 
published Si values of sodium alginate based floating 
tablets 31. 
4.2.3 Paracetamol release studies 
Dissolution studies of paracetamol were carried out for 4 
hours. In this time interval, various release profiles could 
be observed but two main types could be distinguished 
and identified: rapid disintegrating – and prolonged drug 
release. 
Those tablets in which sodium alginate concentration 
was in lower level (-1: 0.5 %) released the API fast. 
Floating tablets with more than 17.82 % sodium alginate 
showed sustained release. This phenomenon may be due 
to that 0.5 % sodium alginate concentration was not 
enough to create coherent structure, thus the effect of L-
HPCs could manifest. On the other hand, floating tablets 
with sustained release could produce maximally 
32.99±3.40 % dissolution after 4 hours. In the analysis of 
variance (ANOVA), two sections could be identified 
based on significance of factors. All dissolution data were 
fitted with quadratic model (p<0.0001). In the first time 
period (from 5 to 45 min), sodium alginate (X1), L-HPC 
(X2) and their interaction (X1X2) were significant 
(p<0.05). At 45 min, categorical factor (X3) became 
significant, too. In the second period (from 1 to 4 hours), 
sodium alginate and the categorical factor were only 
significant (p<0.05), which indicated that the influence of 
L-HPC was not permanently significant on dissolution 
only until 45 minutes. Difference between L-HPC types 
could only be observed in this period. 
4.2.4 Clarithromycin release studies 
In vitro dissolution studies of all floating tablets were 
performed for 6 hours and its result are depicted in 
(Fig.8). 
 
The most rapid dissolution could be observed at MF07 
(sodium alginate: 5.0 %, L-HPC B1: 45.0 %, sodium 
bicarbonate: 13.0 %) having total dissolution after 60 
minutes. Compositions with more than 5.0 % sodium 
alginate (10.0 or 15.0 %) could not produce more than 
26.87±1.05 % dissolution after 6 hours. In the case of 5.0 
% sodium alginate, the least released amount of 
Clarithromycin was 80-82 % (MF01, MF05). 
Standard deviations (SD) of all dissolution data were also 
analyzed with ANOVA and sodium alginate was found as 
a significant factor influencing SD values (p<0.05). The 
more sodium alginate quantity the tablets had the less 
SD values were observed, which consequently could 
influence manufacturing reproducibility. 
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Fig.8. Dissolution profiles of floating tablets (Optimization Project) 
 
4.2.5 Drug release kinetics 
Evaluation of Clarithromycin release revealed that 
tablets having sustained dissolution (MF2, MF4, MF6, 
MF8, MF10, MF11, MF12, MF13, MF14, MF15) can be 
characterized by Higuchi model, which refers to drug 
diffusion from polymer matrices. These floating 
tablets contained 10.0 or 15.0 % sodium alginate. In 
the case of low sodium alginate concentration (5.0 %), 
none of the applied models fitted significantly. Result 
of kinetics analysis is shown in Table 10. The best fitted 
release model of MF_OPT was first order kinetics, but 
due to the biphasic dissolution coefficient of 
determination was only R
2
=0.820. 
 
Table 7. Result of model dependent evaluation of drug release (optimization project) 
                           Zero order model         First order model             Higuchi model                              Weibull model 
Sample m n 
R
2             
m 
n 2 
    R2 
m n 2 
R2 
m n 2 
R2 
  MF1 0.23 37.64 0.509   -0.05 4.08 0.678 4.81 18.53 0.693 0.83 -3.54 0.728 
MF2 0.06 1.82 0.964   -0.00 4.59  0.969 1.09 -1.92 0.980 0.82 -6.12 0.939 
MF3 0.28 48.88 0.518    -0.02 4.20  0.896 5.65 26.63 0.693 0.90 -3.20 0.860 
MF4 0.08 6.75 0.857    0.00 4.54  0.883 1.43 1.64 0.944 0.63 -4.58 0.758 
MF5 0.18 46.33 0.373    0.00 3.91  0.500 3.77 30.87 0.546 0.60 -2.44 0.664 
MF6 0.03 7.34 0.808    0.00 4.53  0.812 0.61 5.15 0.888 0.24 -3.20 0.917 
MF7 2.00 24.71 0.658    -0.08 4.55  0.817 19.96 -19.83 0.789 1.72 -4.82 0.891 
MF8 0.05 2.03 0.900    0.00 4.59  0.909 0.93 -1.26 0.972 0.84 -6.32 0.919 
MF9 0.24 48.80 0.481    0.00 3.89  0.771 4.92 29.24 0.657 0.72 -2.66 0.785 
MF10 0.06 3.99 0.911    0.00 4.57  0.919 1.12 0.13 0.940 0.58 -4.76 0.906 
MF11 0.07 4.69 0.934    0.00 4.56  0.942 1.16 0.75 0.946 0.49 -4.26 0.942 
MF12 0.06 2.64 0.954    0.00 4.58  0.963 1.15 -1.28 0.977 0.75 -5.66 0.900 
MF13 0.05 2.36 0.958    0.00 4.58  0.963 0.86 -0.55 0.962 0.63 -5.35 0.909 
MF14 0.04 2.53 0.897    0.00 4.58  0.907 0.72 0.00 0.959 0.67 -5.63 0.858 
MF15 0.04 1.53 0.960    0.00 4.59  0.961 0.74 -0.96 0.946 0.72 -6.03 0.887 
MF_OPT 0.22 50.30 0.524    0.00 3.89  0.820 4.40 33.06 0.690 0.59 -2.13 0.816 
 Klio
®
n 
0.56 51.16 0.497    -0.04 3.59  0.618 8.66 23.56 0.671 1.07 -3.07 0.866 
Suppli
®
 
           n 
6.07 -7.26 0.833    -0.34 6.24  0.897 42.31 -76.73 0.899 3.07 -7.23 0.953 
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4.2.6 Ex-vivo mucoadhesion studies 
Mucoadhesion is one of the approaches of 
gastroretentive systems, which can be to combine with 
other gastroretentive technologies. Their combination 
may result in more prolonged gastric retention, with 
which location of drug release can be more predictable. 
This synergic effect is more desirable for drug delivery 
systems with APIs aimed at the site of gastric mucosa. In 
this optimization project, the aim was to design and 
develop a floating tablet containing Clarithromycin for 
Helicobacter pylori eradication from gastric mucosa. 
In the ex vivo mucoadhesive studies, the two most 
frequently performed mucoadhesion measurements 
were done in order to present the potential in 
mucoadhesive properties of MF_OPT tablets: detachment 
force and rheological mucoadhesion studies. 
Ex vivo mucoadhesion studies evaluated the 
mucoadhesion of floating tablets in different ways. 
Detachment force study evaluates the possible 
mucoadhesion in a relatively dry status. Mucoadhesion is 
based on the dehydration theory32. In contrast with the 
rheological method, this indirectly measures 
mucoadhesion based on macromolecular 
interpenetration33. Rheological method interprets the 
viscosity changes, when the tablet components are in 
dissolved and swollen form. 
Detachment force studies were carried with MF_OPT and 
three other tablets with modified composition as 
reference having sodium alginate, L-HPC B1 (MF_OPT_L-
HPC) or both excipient (MF_OPT_EXC) absences from 
composition.  The result of detachment force study   is 
shown in Fig. 9. MF_OPT tablets have resulted in 
remarkably higher detachment force (505.49±45.62 mN) 
compared to MF_OPT_L-HPC (314.91±37.88 mN) and 
MF_OPT_EXC (264.68±15.42 mN). Tablets without L-HPC 
B1 had higher detachment force than the reference 
without both excipients. This study may show the 
potential in the possible physical synergistic effect 
between the applied gel forming polymer and 
disintegrant affected with rapid water absorption. 
 
Fig. 9. Result of the detachment force study of MF_OPT 
(5.0 % sodium alginate, 38.63 %  HPC B1, 8.45 % sodium 
bicarbonate) and reference tablets without sodium 
alginate and/ or L-HPC B1 (MF_OPT – optimized 
composition, MF_OPT_L-HPC – MF_OPT  without L- HPC 
B1,     _OPT_2EXC – MF_OPT without sodium alginate and 
L_HPC) 
Result of MF_OPT tablets with the absence of sodium 
alginate led to splitting of tablets due     to rapid 
hydration effect of L-HPC B1. Less coherence of the tablet 
structure was observed at tablets without sodium 
alginate in the presence of acidic medium, therefore 
these tablets were not evaluated. Low viscosities were 
measured at 3 % mucus (7.63±1.24 mPas) and at 
MF_OPT tablet dispersion (27.57±23.22 mPas). Mixture 
of tablet and mucus showed significant rise of viscosity 
(846.89±78.25 mPas at 2.63 1/s). At low shear rates 
having the greatest interest34, eightfold increase could be 
observed. Flow curve of mixture of tablet and mucus 
showed plastic flow behavior. Result of rheological 
method is shown in (Fig. 10.) 
  
 
tablet 
mucus 
tablet+mucus 
mucoadhesion 
 
Fig.10. Result of ex vivo rheological mucoadhesion studies of 3 % mucus, MF_OPT equilibrated to 3 % L-HPC and sodium 
alginate (tablet), their mixture (tablet + mucus) and calculated viscosity increase signed as ‘mucoadhesion’ 
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4.2.7 In vivo X-ray CT evaluation of floating tablets in 
rat 
In vivo gastric retention of MF_OPT tablets with 10 % 
BaSO4 were examined using rat model, which was 
performed as a correlation to human model in a cost-
effective way in order to gain valuable preliminary 
information. HU values of tablets at sampling  times  
showed (Table 8) that  10% BaSO4  content in tablets  
may result in significantly (p<0.0001) higher  HU value 
in comparison to the liver’s HU as reference (HUliver = 
800). Thus, tablets could be distinguished from tissues 
interfering with the view of the tablets. 
Fig.11. showed the fact that MF_OPT tablets could 
remain in stomach for at least 8 hours. The period of 
gastric retention could be enough regarding the fact 
that more than 96 % of API was released within 6 hours 
based on the results of in vitro spectrophotometric and 
microbiologically detected dissolution studies. After 48 
hours, tablets could be identified in the intestinal tract. 
The prolonged residence time in intestinal region may be 
due to the effect of anesthesia, which effect is published 
by Torjman et al. 35. 
Table.8. Mean Hounsfield Units and quantities of voxels 
inside VOIs of MF_OPT tablets with 10% BaSO4 at 
sampling times 
t Mean Hounsfield unit (HU) 
Quantities of 
voxels 
5 min 1482.35±304.03 1735 
1 h 1165.00±103.23 1132 
2 h 1152.38±106.90 1755 
3 h 1202.83±155.36 1949 
4 h 1194.20±146.70 1815 
6 h 1151.43±104.99 1341 
8 h 1151.27±106.23 1324 
48 h 1197.29±112.15 870 
 
 
Fig. 11. X-Ray CT images of MF_OPT tablets loaded with 10 % barium sulfate at different time periods in transverse (a) 
and in sagittal plane (b) (location of tablets indicated with arrows) 
 
The position of MF_OPT tablet in gastrointestinal tract at 
8 hours is shown with yellow in   (Fig. 12) and (Fig. 13). 
The homogeneity parameter of the tablet could be 
visualized in a spectacular manner. In the Fig. 11/A, 
identifications of voxels were performed in wide range, 
with which the location of tablets could be visualized. In 
(Fig. 11/B), tablet structure may be viewed by the  
Imaging of the dispersion of BaSO4 particles. This fine 
resolution X-Ray CT image visualized the voxels for the 
VOIs of tablet (indicated with yellow colors) and for VOIs 
of background (a conventional grey scale). With the 
application of this technique, valuable information could 
be gained related to the in situ behavior of tablets 
including disintegration, swelling, gas creation etc. 
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Fig.12. Position of MF_OFT tablets in rat at 8 hours A: Identification of tablets with simple X-Ray CT evaluation; B: 
Identification and quantification of tablets with fine resolution X- Ray CT technique applying two different lookup tables 
 
Fig.13. In vivo images of the position and structure of MF_OPT tablet at 8 hour after administration in different planes (1 - 
axial, 2 - coronal, 3 - sagittal) 
4.3 Optimization of technological and 
biopharmaceutical parameters 
In order to determine a composition of a desired floating 
tablet, optimization was carried out based on the 
evaluation of floating behavior and release experimental 
parameters. One of the aims was to minimize amount of 
excipients, since less excipients amount are applied, the 
more active substance(s) can be loaded into tablets. 
Floating parameters were adjusted so that the formulation 
would have the best floating properties within this 
concentration interval manifesting in minimization of tlag 
and maximization of Fmax and Fmax/100mg. The 
proportion of release until the first 30 minutes was 
minimized, after 30 minutes it was maximized. 
Based on the optimization criteria, an optimal composition 
(MF_OPT) was determined having 5.0 % sodium alginate, 
38.63 % L-HPC B1 and 8.45 % sodium bicarbonate by 
Design Expert 7.0.0 software. Floating parameters were 
also ascertained. Dissolutions of two commercially 
available non-floating Clarithromycin generics were tested, 
in order to compare them with the optimized formulation.  
Results showed that dissolution of MF_OPT could be 
regarded to be biphasic release involving an initiative 
rapid - (~60 %) and a prolonged release section (~40 %). 
MF_OPT tablets had several advantages including a 
biphasic release and remarkable floating parameters 
compared to the rapidly released Clarithromycin from the 
two approved tablets. 
5. CONCLUSION 
The floating-, swelling behavior and dissolution of the 
preliminary floating tablets were highly affected by the 
amount of sodium alginate (X1) in the compositions. L-HPC 
resulted in rapid disintegration, but this effect could only 
be manifested, when lower quantity of the matrix former 
(sodium alginate in 0.5 %) was present, when sodium 
alginate was applied in 17.82 and 35.05 %, then high 
swelling capability and sustained dissolution could be 
observed as well as longer floating lag time and floating 
time, L-HPC as numerical factor (X2) was significant in 
several cases, but its effect was less than the effect of 
sodium alginate concentration (in this concentration 
range), categorical factor (X3) was only significant at 
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dissolution after 45 min, hence the significance could be 
identified but the difference was not remarkable, therefore 
for further studies L-HPC B1 was used considering its 
better flowability properties Floating lag time data 
indicated that 8 % sodium bicarbonate may have to be 
increased in order to achieve faster start of buoyancy, the 
range of L-HPC and sodium alginate concentrations was 
too broad, thus further adjustment in this interval was 
required in order to create a floating drug delivery system 
with desirable floating, swelling, dissolution properties. 
Clarithromycin dissolution kinetic results showed various 
release behavior.  Trend could be observed that best fitting 
model of releases from floating tablets with 10.0 or 15.0 % 
sodium alginate was Higuchi model. Optimization of 
factors could be done by the use of optimization criteria. 
The optimized composition contained 5.0 % sodium 
alginate (X1), 38.63 % L-HPC B1 (X2), 8.45 % sodium 
bicarbonate (X3). The optimized formulation showed 
promising properties including low floating lag time 
(tlag=13.25±0.50 s), high floating force (Fmax=12.75±1.87 
mN) and biphasic drug dissolution. Between drug and 
excipients, studies did not reveal any interactions. X-Ray 
CT imaging result showed a prolonged in vivo retention of 
floating tablets in gastric region.  
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